-$0.92 Earnings Per Share Expected for Audentes Therapeutics Inc (BOLD) This Quarter

Equities research analysts expect Audentes Therapeutics Inc (NASDAQ:BOLD) to announce earnings of ($0.92) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Audentes Therapeutics’ earnings. The lowest EPS estimate is ($1.08) and the highest is ($0.84). Audentes Therapeutics reported earnings of ($0.91) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 1.1%. The business is expected to issue its next quarterly earnings results on Thursday, March 8th.

On average, analysts expect that Audentes Therapeutics will report full-year earnings of ($3.50) per share for the current year, with EPS estimates ranging from ($3.69) to ($3.42). For the next year, analysts expect that the company will post earnings of ($3.70) per share, with EPS estimates ranging from ($5.31) to ($3.20). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Audentes Therapeutics.

Several analysts have issued reports on BOLD shares. Zacks Investment Research upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 23rd. Leerink Swann restated an “outperform” rating and set a $29.00 price objective (up previously from $22.00) on shares of Audentes Therapeutics in a report on Wednesday, November 15th. ValuEngine downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BMO Capital Markets assumed coverage on Audentes Therapeutics in a report on Tuesday, December 5th. They issued an “outperform” rating and a $35.00 target price on the stock. Finally, BidaskClub downgraded Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $34.00.

In other news, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $30.88, for a total value of $555,840.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Suyash Prasad sold 8,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $28.53, for a total value of $228,240.00. The disclosure for this sale can be found here. 47.30% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Schwab Charles Investment Management Inc. increased its holdings in Audentes Therapeutics by 139.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 25,600 shares of the biotechnology company’s stock worth $490,000 after buying an additional 14,900 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Audentes Therapeutics by 180.7% in the second quarter. Bank of New York Mellon Corp now owns 52,900 shares of the biotechnology company’s stock worth $1,012,000 after buying an additional 34,057 shares during the last quarter. Teachers Advisors LLC increased its holdings in Audentes Therapeutics by 342.5% in the second quarter. Teachers Advisors LLC now owns 26,926 shares of the biotechnology company’s stock worth $515,000 after buying an additional 20,841 shares during the last quarter. TIAA CREF Investment Management LLC increased its holdings in Audentes Therapeutics by 459.3% in the second quarter. TIAA CREF Investment Management LLC now owns 64,497 shares of the biotechnology company’s stock worth $1,234,000 after buying an additional 52,965 shares during the last quarter. Finally, Nationwide Fund Advisors increased its holdings in Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after buying an additional 6,384 shares during the last quarter. Institutional investors own 64.94% of the company’s stock.

Shares of Audentes Therapeutics (BOLD) opened at $33.51 on Thursday. Audentes Therapeutics has a twelve month low of $13.90 and a twelve month high of $41.80.

COPYRIGHT VIOLATION WARNING: “-$0.92 Earnings Per Share Expected for Audentes Therapeutics Inc (BOLD) This Quarter” was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/02/25/0-92-earnings-per-share-expected-for-audentes-therapeutics-inc-bold-this-quarter.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply